English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12441/13613 (91%)
造訪人次 : 2352344      線上人數 : 93
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14183


    題名: Development of COVID-19 vaccines through augmenting antiviral immune responses: A systematic review and meta-analysis
    作者: Ma, KSK;Lee, CC;Liu, KJ;Wang, LT
    貢獻者: National Institute of Cancer Research
    摘要: We aim to evaluate strategies on augmentation of host immunity against Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) infection. We searched clinical trials registered at the National Institutes of Health through December, 2020, and conducted analyses on inoculated population, involved immunological processes, source of injected components, and trial phases. We then searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials for their corresponding reports. A bivariate random‐ effects meta‐analysis was used to derive the pooled estimate of seroconversion and adverse events (AEs). A total of 540,269 participants were enrolled in 225 identified trials. The working mechanisms included heterologous immunity, active immunity, passive immunity, and immunotherapy. A total of 2,565 healthy adults from 10 clinical trials were included for meta‐analyses. The odd ratio (OR) was 90.82 for kinetics of serologic responses to anti‐SARS‐CoV‐2 antibody IgG titer (95% CI =36.1 – 228.49; p< 0.00001). The pooled ORs were 2.57 for solicited systemic AEs (95%CI =1.57 – 4.21; p = 0.0002), 5.72 for solicited local AEs (95% CI=2.59 – 12.67; p < 0.0001), and 2.08 for unsolicited systemic events (95% CI=1.42 – 3.05; p = 0.0002), compared to placebo or conservative treatment. Among all immune‐augmentative interventions, a paradigm shift to vaccines providing active immunity was observed. The efficacy of these interventions was promising although systemic adverse events were noted.
    日期: 2021-08
    關聯: European Journal of Immunology. 2021 Aug;51(Suppl. 1):395.
    Link to: http://dx.doi.org/10.1002/eji.202170200
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0014-2980&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000753366402130
    顯示於類別:[劉柯俊] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000753366402130.pdf222KbAdobe PDF251檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋